Blog

Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer

Photo from www.bcrf.org

Jul 21, 2024, 21:49

Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X, about a recent paper by Alexios Matikas et al., commenting:

“Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: Final Results of the PANTHER Trial
mFU: 10.3years
Dose-dense adjuvant regimen is statistically associated with better RFS, EFS, and DDFS. OS is not significant (HR:0.82).”

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

Journal: Journal of Clinical Oncology

Author: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis and Jonas Bergh

Source: Yakup Ergün/X

Alexios Matikas Antalya City Hospital Breast Cancer cancer DDFS EFS Jonas Bergh OncoDaily Oncology PANTHER Trial RFS Richard Greil Theodoros Foukakis Volker Möbus Yakup Ergün

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage